Health Robotics recently declared that Korean-based market leader Dongbang Healthdyne will support a new indirect sales and service channel for its high-efficiency i.v.STATION ONCO, i.v.STATION, and i.v.SOFT products.
By promoting affordable and safe Intravenous Admixture Compounding Automation to hospitals Health Robotics will remain as a pioneer in the global healthcare industry.
According to Dongbang Healthdyne' President, Byung Ahn, with growing life expectancy of its population, Korea has witnessed an increase of cancer patients up to three times than before. Hospitals in Korea are challenged with compounding Oncology IV preparations. According to market research, Health Robotics has been flourishing with the development of its G2 i.v.STATION ONCO.
Health Robotics' Executive Vice President, Gaspar DeViedma says that Health Robotics' G2 Cancer Therapy Compounding robot for syringes and I.V. Bags has become significant with the launch of i.v.STATION ONCO within the worldwide healthcare market. i.v.STATION ONCO’s technological innovations include its potential to leverage pre-attached lines to IV Bags; automatic tamper-evident syringe capping; small footprint range 15% to 25% of the size or weight of other IV Robots; RFID support and rapid throughput up to 40 doses per hour instead of 20 doses per hour. In addition to i.v.STATION and i.v.SOFT, Health Robotics will also promote i.v.STATION ONCO to have a leading position in the industrial markets of Korea that will ultimately lead to a significant expansion.